VEGFA and glioblastoma: BEV, a monoclonal anti-VEGF-A IgG1 antibody, was granted accelerated approval by the FDA in 2009, and subsequently authorized in Switzerland for relapsing GBM following two single-arm phase II trials in the recurrent GBM setting [12,13].